Add to ORKGSummary In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) has been associated with several cancers and this cell surface molecule has been recognized both as a tumor marker and as a potential target to disrupt progression of cancer. Here we summarize what is known about CDCP1 including its structural features, expression in normal and cancerous tissues, and the in vitro experiments and studies in animal models that have provided the key insights into its potential role in tumor formation and metastasis in humans. We conclude by highlighting opportunities and challenges in targeting CDCP1 in cancer. 2009 IUBMB IUBMB Life, 61(7): [723][724][725][726][727][728][729][730] 200
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing...
Background: Deregulated expression of the transmembrane glycoprotein CDCP1 (CUB domain-containing pr...
CUB-domain-containing protein 1 (CDCP1) is an integral membrane glycoprotein with potential as a mar...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signal...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing...
Background: Deregulated expression of the transmembrane glycoprotein CDCP1 (CUB domain-containing pr...
CUB-domain-containing protein 1 (CDCP1) is an integral membrane glycoprotein with potential as a mar...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signal...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Inste...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...